27 results
8-K
KROS
Keros Therapeutics Inc
22 May 23
Keros Therapeutics Presents Preclinical and Clinical Data from its KER-012 Program at the American Thoracic Society International Conference
9:01am
announcing additional biomarker data from its completed Phase 1 clinical trial of KER-012 in healthy post-menopausal women, being presented
8-K
EX-99.1
KROS
Keros Therapeutics Inc
22 May 23
Keros Therapeutics Presents Preclinical and Clinical Data from its KER-012 Program at the American Thoracic Society International Conference
9:01am
of KER-012 in healthy post-menopausal women at the American Thoracic Society (“ATS”) 2023 International Conference, held from May 19 through May 24, 2023 … . From our completed Phase 1 clinical trial of KER-012 in healthy post-menopausal women, we presented new data with observed sustained changes
8-K
EX-99.1
KROS
Keros Therapeutics Inc
4 May 23
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2023 Financial Results
4:01pm
Post-Menopausal Women”
Session Name: A26: Precision-Based Approaches to Pulmonary Vascular Disease
Date and Presentation Time: May 21, 2023; 9:00
8-K
EX-99.1
KROS
Keros Therapeutics Inc
12 Sep 22
Other Events
6:03am
preliminary clinical data from the Part 2 multiple ascending dose (“MAD”) portion of its Phase 1 clinical trial of KER-012 in healthy postmenopausal women … Postmenopausal Women was Generally Well Tolerated and Increased Biomarkers of Bone Formation, Supportive of a Bone Anabolic Mechanism
This Phase 1
8-K
KROS
Keros Therapeutics Inc
12 Sep 22
Other Events
6:03am
in healthy postmenopausal women, as well as preclinical data evaluating the bone anabolic activity of RKER-050, a research form of KER-050, in a mouse
8-K
EX-99.1
9a423ga
4 Aug 22
August 2022 Corporate Presentation
5:13pm
8-K
EX-99.1
q9l0h
4 Aug 22
Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results
4:09pm
8-K
EX-99.2
xjso 4qzm
18 May 22
Keros Therapeutics Announces Preliminary Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating KER-012 in Healthy Volunteers
6:12am
10-K
hjugs44mqb900sq
25 Mar 21
Annual report
8:23am
424B4
lp2nfidea oxgsk7
13 Nov 20
Prospectus supplement with pricing info
4:02pm
8-K
EX-99.1
v07jlju1bd
10 Nov 20
Other Events
5:14pm
DRS
m47wby2
3 Nov 20
Draft registration statement
12:00am
8-K
EX-99.1
tydw80po
20 Oct 20
Other Events
8:04am
8-K
EX-99.1
5s1f28xyeux44 spr
12 Jun 20
Other Events
7:08am
8-K
keh 61yjp
12 Jun 20
Other Events
7:08am
10-Q
ud70lkwmx5o5v0vqw
22 May 20
Quarterly report
7:16am